key: cord-0760930-3d50tl8y
authors: Barry, Mazin; Althabit, Nouf; Akkielah, Layan; AlMohaya, AbdulEllah; Alotaibi, Muath; Alhasani, Sara; Aldrees, Abdulwahab; AlRajhi, Abdulaziz; AlHiji, Ali; Almajid, Fahad; AlSharidi, Aynaa; Al-Shahrani, Fatimah S.; Alotaibi, Naif H.; AlHetheel, Abdulkarim
title: Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patients in a MERS-CoV Referral Hospital during the Peak of the Pandemic
date: 2021-03-23
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.03.058
sha: ea052200241a3fb41b083bac194f8606c8656e41
doc_id: 760930
cord_uid: 3d50tl8y

Objective To describe the clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak months of the pandemic. Design A single-center case series of hospitalized individuals with confirmed SARS-CoV-2 infections in King Saud University Medical City (KSUMC), an academic tertiary care hospital in Riyadh, KSA. Clinical and biochemical markers were documented. Risks for ventilatory support, intensive care unit (ICU) admission, and death are presented. Results Out of 12,688 individuals tested for SARS-CoV-2 by RT-PCR, 2,683 (21%) were positive for COVID-19. Of the latter, 605 (22%) patients required hospitalization with a median age of 55 years, and 368 (61%) were male. The most common comorbidities were hypertension (43%) and diabetes (42%). Most patients presented with fever (66%), dyspnea (65%), cough (61%), elevated IL-6 (93.5%), D-dimer (90.1%), CRP (86.1%), and lymphopenia (41.7%). No MERS-CoV co-infection was detected. Overall 91 patients (15%) died, risk factors associated with mortality were age of 65 years or older OR 2.29 [CI 1.43–3.67], presence of two or more comorbidities OR 3.17 [CI 2.00–5.02], symptoms duration of seven days or less OR 3.189 [CI (1.64 – 6.19]) lymphopenia OR 3.388 [CI 2.10–5.44], high CRP OR 2.85 [CI 1.1–7.32], high AST OR 2.95 [CI 1.77–4.90], high creatinine OR 3.71 [CI 2.30–5.99], and high troponin-I OR 2.84 [CI 1.33–6.05]. Conclusion There is a significant increase in severe cases of COVID-19. Mortality was associated with older age, shorter symptom duration, high CRP, low lymphocyte count, and end-organ damage.

Since the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Wuhan, China, in December 2019 and the declaration of the coronavirus (COVID-19) as a pandemic by the World Health Organization (WHO) on March 11, 2020, it has infected more than 88 million individuals around the world with almost two million deaths as of January 7, 2020 (World Health Organization, n.d.) . In the Kingdom of Saudi Arabia (KSA), 363,582 individuals have been infected with 6,282 deaths, with a national case fatality ratio (CFR) of 1.7% (Saudi Arabia Ministry of Health, n.d.), which is less than reported by the United States (CFR of 2.7%), Italy (CFR of 9.5%), and China (CFR 5.2%) (World Health Organization, n.d.) . Many studies have been published describing patient demographics, clinical course, and outcomes from those J o u r n a l P r e -p r o o f countries (Argenzian et al., 2020; Docherty et al., 2020; Lechien et al., 2020; Richardson et al., 2020 ).

The first case of COVID-19 in KSA was reported on March 2, 2020 (Barry et al., 2020b) , and the peak of the pandemic was reported in June and July 2020, with 4,919 individuals being the highest number of cases recorded in a single day on June 18, 2020 (Saudi Arabia Ministry of Health, n.d.;

World Health Organization, n.d.).

The Middle East Respiratory Syndrome Corona Virus (MERS-CoV) originated in KSA (Zaki et al., 2012) and is the only country in the world where it is still endemic, causing multiple nosocomial outbreaks (Alenazi et al., 2017; Amer et al., 2018; Assiri et al., 2013; Balkhy et al., 2016; Barry et al., 2020c; Drosten et al., 2015; Fagbo et al., 2015; Oboho et al., 2015) . At time of writing, the most recent reported case of MERS-CoV was on May 31, 2020 (Saudi Arabia Ministry of Health, n.d.). As per the latest situation update from the WHO, a total of 2,519 laboratoryconfirmed MERS-CoV infections, including 866 associated deaths (CFR 34.3%), were reported globally. Most of these cases were in KSA (2,121 cases), including 788 related deaths (CFR 37 .1%) between June 2012 and January 2020 (WHO, n.d.) .

We describe the clinical characteristics and outcome of hospitalized patients with COVID-19 in an academic hospital, which serves as a MERS-CoV referral center during the peak months of the J o u r n a l P r e -p r o o f pandemic in KSA. This is a follow-up to our previously published data from the same hospital during the early months of the pandemic (Barry et al., 2020a) .

This is a single center case series conducted at King Saud University Medical City (KSUMC) of hospitalized COVID-19 patients during the peak of the COVID-19 pandemic, between June 1, 2020 to August 31, 2020. We included all individuals aged 14 years or older who were hospitalized for at least 24 hours, with real-time reverse transcriptase polymerase chain reaction (RT-PCR) confirmed COVID-19 during the study period. Patients who were still hospitalized by the end of the study period were followed until discharge or in-hospital death, with the last follow-up event 

During the peak of the COVID-19 pandemic in KSA from June 1 to August 31, 2020, a total of 12,688 patients aged 14 years and above were tested for COVID-19 by RT-PCR at KSUMC, Riyadh. Of those, 2,683 patients (21.1%) tested positive, and of those tested positive, 606 patients (22.6%) required hospitalization. Only one patient was lost to follow-up due to transfer to another hospital, and the remaining 605 patients met the inclusion criteria ( Figure 1 ). Demographic characteristics are shown in Table 1 . 

Of 445 (73.6%) admitted to the ward, 78 (15%) required transfer to the ICU, while 82 (13.5%)

were admitted directly to the ICU, for a total of 160 (26.4%) patients requiring ICU admission.

Overall, 514 (85%) were discharged from hospital, while 91 patients (15%) died during their hospital stay. The median time to discharge or mortality was 7 and 13 days, respectively. Reasons for ICU admission included respiratory distress (79.4%), transfer from another hospital on mechanical ventilation (6.3%), hypotension (5.6%), decreased level of consciousness (3.1%), cardiac/respiratory arrest (1.9%), and others ( Table 2) . Out of those who required ICU admission, J o u r n a l P r e -p r o o f or no comorbid illnesses. Of those who required ICU admission, 32.5% had a temperature ≥38°C and 69.4% had a respiratory rate >24/min in the first 24 hours of admission. In the ICU, 38.1%, 46.9%, and 45.6% of patients needed vasopressors, mechanical ventilation, and non-invasive ventilation, respectively. One patient in the ICU required extracorporeal membrane oxygenation (ECMO) but did not survive. (18) IQR: interquartile range, DKA: diabetic ketoacidosis, HFNC: high-flow nasal cannula, BIPAP: bilevel positive airway pressure, CPAP: continuous positive airway pressure, ECMO: extracorporeal membrane oxygenation

The most common presenting symptoms were fever in 65.5% of patients, dyspnea (65%), cough (61%), and gastrointestinal symptoms (37.5%), which included any of the following: nausea, vomiting, diarrhea, and fatigue (26%) (Figure 2 ). The median duration of symptoms (IQR) was five days. In the first 24 hours of presentation, median oxygen saturation (IQR) was 94%, median temperature (range) was 37.3°C (36°-40.2°C), median respiratory rate (IQR) was 23 bpm, and median systolic blood pressure (IQR) was 118 mmHg.

In the first 48 hours of admission, laboratory investigations revealed that 9.8% of patients had a WBC count of less than 4.0 x 10 9 /L, while 13.6% of patients had a platelet count of less than 150

x 10 9 /L, and 583 (41.7%) had a lymphocyte count less than 1.0 x 10 9 /L. Most patients showed raised Interleukin-6 (IL-6), D-dimer, aspartate aminotransferase (AST), C-reactive protein (CRP) and ferritin levels, in addition to a prolonged QT interval on baseline electrocardiogram (ECG) ( Table 3) . During admission, chest X-rays (CXRs) and CT scans were obtained from 545 and 45 patients, respectively. One hundred and fifty-nine (29.2%) patients had normal CXRs, while the other 69.8% had evidence of lung infiltrates. Of those CXRs showing infiltrates, 88.5% were 

Treatment of COVID-19 patients varied according to severity and complications, including corticosteroids, interferon beta, anticoagulants, tocilizumab, and anti-viral, anti-malaria, and antibacterial agents (Table 4 ). The most common treatment regimen included hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, steroids, and tocilizumab (Table 4) . (Table 4 ).

Other factors, namely having two or more comorbidities, RR of more than 24/min in the first 24 hours, a low lymphocyte count (<1 x10^9/L), a high PCT (>0.5 ng/mL), markers of end organ damage like high aspartate transaminase (AST) levels (>37 units/L), high creatinine levels (>115 mcmol/L), high troponin I (>100 ng/L), and CXR infiltrates on arrival were all significantly associated with more severe disease, ICU admission, and mortality (Table 5 ). 

In this detailed COVID-19 case series from a country endemic with MERS-CoV, we describe the clinical characteristics and risk factors in hospitalized patients aged 14 years and older with laboratory confirmed SARS-CoV-2 infection during the peak months of the pandemic. This study is a follow-up to our first detailed case series, which emerged from KSA during the early months of the pandemic (Barry et al., 2020a) . It reveals that a fifth of patients tested for COVID-19 were positive and 23% required hospitalization. Of those, 26% required ICU care, which is a significant rise from the earlier months, in which only a tenth of all patients were tested positive, 16% required hospitalization, and 22% required ICU care. In this analysis, the COVID-19 case fatality rate was 3.4% of all those who tested positive in our hospital, which is also a significant rise from 0.2% in the preceding months. Among all hospitalized patients, 15% died, and for the subset of patients requiring ICU admission, 46% died, compared to 12% and 50%, respectively, in the early months.

As in the earlier cohort, from 194 (32%) patients who were also tested for MERS-CoV as per case definition, none had any evidence of co-infection.

In-hospital mortality was associated with advanced age (≥ 65 years), presence of comorbidities, severity of infection upon presentation, and presence of end-organ damage. In a study conducted in Georgia in the United States, the CFR was 17.1% for non-ICU cases and 30.6% for ICU cases (Gold et al., 2020) . Another study from Detroit presented a similar CFR of 5.1% and 39% for general practice and ICU cases, respectively (Suleyman et al., 2020) . In China, a meta-analysis of COVID-19 clinical characteristics revealed an overall CFR of 3.6% (Fu et al., 2020) , while in UK, a study of 20,133 patients showed a CFR of 26% with median age of victims to be 80 years old (Docherty et al., 2020) .

Hospital stay was notably longer among patients hospitalized during the peak (median 17 days) in comparison to those hospitalized at the beginning of the pandemic in KSUMC (median 5 days) (Barry et al., 2020a) , which indicates worsening disease severity and an increase in severe/critical cases. These findings are consistent with findings from Wuhan, China, describing the clinical characteristics and outcomes of severe or critical COVID-19, which showed a mean hospital stay of 15 days . Another study from China showed a mean hospital stay of 11 days in general and 21 days for severe/critical cases (Zhou et al., 2020) . In the US, it was 5 days for nonsevere cases and 15 days for severe cases requiring ICU admission (Suleyman et al., 2020) .

The predominant symptoms were fever, cough, and dyspnea. Our cohort showed a higher percentage of dyspnea (65%) compared to other reports from KSA (27%) (Sarfraz et al., 2020) , Turkey (27.8%) (Altunok et al., 2020) , and China (6.9%) (Tian et al., 2020) . Regarding the 160 patients admitted to the ICU, the fatality rate (CFR) was 47.6%. In comparison, a case series from

Kuwait showed a similar CFR of 43.7% (Ayed et al., 2020) , but was much less than that reported from Spain (72.9%) (Jiménez et al., 2020) . There was no statistically significant difference in age group or gender for ICU admission, which is similar to other studies (Ayed et al., 2020; Jiménez et al., 2020) . This could be attributed to a younger population with only 150 patients aged ≥65

years, while other cohorts had higher numbers (Richardson et al., 2020 (Ayed et al., 2020) although they had a significant rate of infiltrates upon presentation. Low lymphocyte count, high AST, acute kidney injury (AKI), and raised J o u r n a l P r e -p r o o f inflammatory markers (ferritin, CRP, and PCT) were all observed as factors associated with severe disease, ICU admission, and death, which is consistent with other studies (Lechien et al., 2020; Richardson et al., 2020) .

The majority of pregnant women included in our study were asymptomatic, with no associations identified between gestational age and disease severity, which is consistent with the results of a large meta-analysis including published data from different countries and populations (Juan et al., 2020) . COVID-19 status could not be retrieved for all neonates; however, no neonatal or maternal deaths were recorded.

Multiple drugs were used to manage the conditions of hospitalized patients, and steroids were commonly used among different disease spectra. Survival rates were compared between the five groups (asymptomatic, URTI, mild and severe pneumonia, and critically ill), and steroids were found to be successful in the asymptomatic and those with pneumonia in addition to the severe group, compared with the critically ill patients where the survival rate was poor, which is most likely secondary to hospital stay complications, including pulmonary embolism, cardiopulmonary arrest, and anoxic brain damage. The RECOVERY randomized control trial conducted among COVID-19 patients, where dexamethasone was given to 2,104 patients and compared to 4,321 patients managed by standard of care, found that 28-day mortality was lower in the group who received dexamethasone while on oxygen therapy, either supplemental or invasive (RECOVERY Collaborative Group, 2020). Another prospective meta-analysis in 1,703 critically ill patients that J o u r n a l P r e -p r o o f compared systemic glucocorticoids with standard care showed that steroids lowered 28-day mortality (Sterne et al., 2020) .

Several drugs were used to manage COVID-19, including remdesivir (Sanders et al., 2020) . In our center, remdesivir was given as part of the WHO Solidarity trial (WHO Solidarity Trial Consortium, 2020), although the number was extremely low, and no mortality was observed. A double-blind, randomized, placebo-controlled trial was conducted by Beigel et al. (2020) among 1,062 patients who underwent randomization, with 541 assigned to remdesivir and 521 to placebo.

It was found that remdesivir predicted a shorter recovery time in those with lower respiratory tract infection compared to the placebo group.

Triple therapy that includes protease inhibitors, interferon, and ribavirin was used for a small number of patients, also as part of the Solidarity trial (WHO Solidarity Trial Consortium, 2020).

Of five patients in critical condition who received it, only two survived. A multicenter, prospective, open-label, randomized phase 2 trial with COVID-19 in Hong Kong showed that early triple therapy was superior to lopinavir-ritonavir alone in regard to shortening symptoms duration and hospital stay (Hung et al., 2020) .

Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) . It was given to 28 critically ill patients with 18 mortalities. A cohort studying the association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19 was conducted by Gupta et al., and the main outcome of early treatment with tocilizumab showed lower in-hospital mortality rates (Gupta et al., 2020) . Additionally, Salvarani et al. conducted a randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and did not show any disease progression benefit in comparison with standard care (Salvarani et al., 2020) .

Hydroxychloroquine was also used initially for a few patients as part of the Solidarity trial but was soon discontinued when its use was revoked (U.S. Food and Drug Administration, 2020). None of the six patients who received it died; however, only one had a severe case of the virus.

Our study has several limitations, including data emerging from a single center, lack of data on viral load, and epidemiological data. Only a third of patients were tested for MERS-CoV infections.

In conclusion, this follow-up case series found a significant increase in the number of severe cases of COVID-19, mostly in male patients younger than 65 years old. Mortality was associated with older age, multiple comorbidities, shorter symptom duration, tachypnea, abnormal CXR on admission, direct admission to ICU, low lymphocyte count, high CRP, and evidence of end-organ damage. No MERS-CoV co-infections were detected.

This study was approved by the Institutional Review Board at the College of Medicine and King Saud University Medical City (IRB-E20-4979).

J o u r n a l P r e -p r o o f

Identified transmission dynamics of Middle East respiratory syndrome coronavirus infection during an outbreak: Implications of an overcrowded emergency department

Clinical characteristics of adult patients hospitalized with laboratory-confirmed COVID-19 pneumonia

Unusual presentation of Middle East coronavirus leading to a large outbreak in Riyadh during 2017

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series

Hospital outbreak of Middle East respiratory syndrome coronavirus

Assessment of clinical characteristics and mortality-associated factors in COVID-19 critical cases in Kuwait

Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia

Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic Area

Coronavirus disease-2019 pandemic in the Kingdom of Saudi Arabia: Mitigation measures and hospital preparedness

Nosocomial outbreak of the Middle East Respiratory Syndrome coronavirus: A phylogenetic, epidemiological, clinical and infection control analysis

Remdesivir for the treatment of Covid-19-Final report

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Prospective observational cohort study

An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia

Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

Characteristics and clinical outcomes of adult patients hospitalized with COVID-19-Georgia

Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: A retrospective case series study

COVID-19) on maternal, perinatal and neonatal outcome: systematic review

Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019

Clinical characteristics and outcomes of 74 patients with severe or critical COVID-19

Tocilizumab treatment in COVID-19: A single center experience

Ministry of Health Command and Control Center

MERS-CoV outbreak in Jeddah -A link to health care facilities

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia

Pharmacologic treatments for coronavirus disease 2019 (COVID-19)

Clinical characteristics of patients with COVID-19 in Saudi Arabia-A single center experience

Saudi Arabia Ministry of Health. COVID 19 Dashboard: Saudi Arabia

Saudi Arabia Ministry of Health. MOH health events: Epi-week 23

Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19. (Version 21)

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19

Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in Metropolitan Detroit

Dexamethasone in hospitalized patients with Covid-19 -Preliminary report

Characteristics of COVID-19 infection in Beijing

Food and Drug Administration. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine

Repurposed antiviral drugs for Covid-19 -Interim WHO Solidarity trial results

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

None.

All authors gave their consent for publication.

All the data for this study will be made available upon reasonable request to the corresponding author.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

None declared.